The role of PPIs in patients with angiographic embolization for non-variceal up gastrointestinal bleeding

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100042593

Enrollment

Unknown

Registered

2021-01-23

Start date

2021-01-25

Completion date

Unknown

Last updated

2021-05-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal Bleeding

Interventions

High dose:treat with high dose PPI

Conventional dose:treat with conventional dose PPI

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged > 18 years; 2. new up gastrointestinal bleeding (as hematemesis, melena, bloody fluid from gastric tube); 3. need for angiographic embolization (including the patients with unsuccessful gastroscopic hemostasis or without chances for endoscopic treatment or with a high surgical risk).

Exclusion criteria

Exclusion criteria: 1) Refuse PPIs use after angiographic embolization; 2) variceal bleeding results from portal hypertension; 3) complicated with systemic hematological diseases; 4) cancer; 5) allergic to contrast agents; 6) uremia patients with dialysis; 7) Pregnancy or lactate; 8) refuse to attend the study; 9) be included in other clinical trials.

Design outcomes

Primary

Measure	Time frame
rebleeding ratio in 30 days;	—

Countries

China

Contacts

Public ContactXiao Xue

Gastroenterology Department, West China Hospital

xx_1299@163.com+86 15982175701

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026